Abstract | BACKGROUND: METHODS: We recruited 24 girls with T1D. The participants had hyperandrogenism and displayed suboptimal metabolic control. The patients were enrolled in a randomized, double-blind, placebo-controlled trial. One group received metformin (850 mg bid) and the other group received a placebo. Treatment was administered for 9 months. Ovulation, steroids and gonadotropin levels were evaluated. RESULTS: CONCLUSION: Treating hyperandrogenic T1D adolescents with metformin significantly decreased the serum androgens compared to the placebo, but metformin therapy did not significantly affect clinical parameters, such as hirsutism, ovulation and metabolic control.
|
Authors | Ethel Codner, Germán Iñíguez, Patricia López, Verónica Mujica, Francisca C Eyzaguirre, Sylvia Asenjo, Isabel Torrealba, Fernando Cassorla |
Journal | Hormone research in paediatrics
(Horm Res Paediatr)
Vol. 80
Issue 5
Pg. 343-9
( 2013)
ISSN: 1663-2826 [Electronic] Switzerland |
PMID | 24280743
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gonadotropins
- Hypoglycemic Agents
- 17-alpha-Hydroxyprogesterone
- Metformin
- Androsterone
|
Topics |
- 17-alpha-Hydroxyprogesterone
(blood)
- Adolescent
- Adult
- Androsterone
(blood)
- Diabetes Complications
(blood, drug therapy, physiopathology)
- Diabetes Mellitus, Type 1
(blood, drug therapy, physiopathology)
- Double-Blind Method
- Female
- Gonadotropins
(blood)
- Humans
- Hyperandrogenism
(blood, drug therapy, etiology, physiopathology)
- Hypoglycemic Agents
(administration & dosage)
- Metformin
(administration & dosage)
- Ovulation
(blood, drug effects)
|